Kazia Therapeutics Limited KZIA

NAS: KZIA | ISIN: US48669G1058   30/04/2025
3,590 USD (+3,46%)
(+3,46%)   30/04/2025

31 maart 2025 · Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil · Persbericht

12 september 2024 · Kazia Executes Licensing Agreement With Qimr Berghofer · Persbericht

10 juli 2024 · Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma · Persbericht

27 juni 2024 · Kazia Announces Upcoming Dipg Data Presentations At Ispno And Publication In European Journal Of Cancer · Persbericht

23 mei 2024 · Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement · Persbericht

1 mei 2024 · Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients · Persbericht

21 maart 2024 · Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases · Persbericht

13 maart 2024 · Kazia announces presentation of new data at AACR Annual Meeting · Persbericht

21 februari 2024 · Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint · Persbericht

18 januari 2024 · Kazia Continues Board Renewal With Two New Appointments · Persbericht

6 december 2023 · Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering · Persbericht

1 december 2023 · Kazia Therapeutics Announces $2 Million Registered Direct Offering · Persbericht

10 november 2023 · Kazia Announces Publication In Molecular Cancer Therapeutics Highlighting Paxalisib Preclinical Data In Melanoma · Persbericht

1 november 2023 · Kazia Therapeutics Provides Preliminary Update From Ongoing Phase 2 Study Of Paxalisib In Primary Cns Lymphoma · Persbericht

23 oktober 2023 · Kazia Therapeutics Announces Clinical Data At Esmo 2023 From Ongoing Phase 1 Evt801 Study · Persbericht

11 oktober 2023 · Kazia announces voluntary delisting from ASX · Persbericht

5 oktober 2023 · Kazia Therapeutics Announces Presentations At Upcoming Scientific Meetings · Persbericht

29 september 2023 · Kazia Therapeutics Announces Acceptance Of Late-Breaking Abstract And Oral Presentation Of Pnoc022 Clinical Data At 2023 Society For Neuro-Oncology Annual Meeting · Persbericht

6 juli 2023 · Kazia's Paxalisib Receives Fast Track Designation From Fda For Treatment Of Solid Tumor Brain Metastases Harboring Pi3K Pathway Mutations In Combination With Radiation Therapy · Persbericht

8 juni 2023 · KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA · Persbericht

Mijn selecties